Randomized clinical trials in gastrointestinal stromal tumors - Wikidata - wikimedia - TriplyDB

Randomized clinical trials in gastrointestinal stromal tumors

Randomized clinical trials in gastrointestinal stromal tumors

http://www.wikidata.org/entity/Q35188114

about

In vivo fluorescence imaging of gastrointestinal stromal tumors using fluorophore-conjugated anti-KIT antibody Sarcoma-The standard-bearer in cancer discovery.

P2860

Q34024845-3C51D851-ED9B-4650-9D08-E33117D195A2 Q55379483-9C19A9B5-07D7-4149-B183-B59AC56E11E9

P2860

Randomized clinical trials in gastrointestinal stromal tumors

http://www.wikidata.org/entity/Q35188114

description

2010 nî lūn-bûn

@nan

2010 թուականի Յունուարին հրատարակուած գիտական յօդուած

@hyw

2010 թվականի հունվարին հրատարակված գիտական հոդված

@hy

2010年の論文

@ja

2010年論文

@yue

2010年論文

@zh-hant

2010年論文

@zh-hk

2010年論文

@zh-mo

2010年論文

@zh-tw

2010年论文

@wuu

name

Randomized clinical trials in gastrointestinal stromal tumors

@ast

Randomized clinical trials in gastrointestinal stromal tumors

@en

type

label

Randomized clinical trials in gastrointestinal stromal tumors

@ast

Randomized clinical trials in gastrointestinal stromal tumors

@en

prefLabel

Randomized clinical trials in gastrointestinal stromal tumors

@ast

Randomized clinical trials in gastrointestinal stromal tumors

@en

P1433

Q35188114-3625F4E5-38DF-4F9E-9A15-ABAA2C830E8A

P1476

Q35188114-B2FE2D82-89AF-4ACA-86C3-4DF4A81E1605

P2093

Q35188114-36F47C25-9A27-481A-B03D-8960435EA113

Q35188114-840C5E41-8DBF-4B41-935C-08C78E9D24AE

Q35188114-D56A252A-0F10-464F-A551-8982ACCC23F1

P2860

Q35188114-2B66F241-1F6A-472D-9E15-66FB938B57E0

Q35188114-32BC44B6-8454-4400-BE50-F4C32E879936

Q35188114-40C519F8-6FF2-47FF-8F95-A390EF241D6B

Q35188114-413B5629-F56A-4F38-B093-DEC6D891AA06

Q35188114-49D302E8-E268-449A-AA93-F3142695C307

Q35188114-5BD1CE6A-223E-420B-95EB-1ACF6064DC43

Q35188114-77A05797-F1F3-4B38-A8C7-88AD9762956E

Q35188114-7E228139-FF74-4917-A1ED-58561DE77221

Q35188114-90B27894-8438-41D3-8410-DF51037119C2

Q35188114-9E36BDD6-D4F2-43A2-91C9-295E839F3074

P304

Q35188114-FEF02C47-E99C-42DF-8CC8-55EA08487161

P31

Q35188114-158374C1-1D33-42C4-AFF0-115AB67C9942

P356

Q35188114-93A0F2EA-2F36-4DE4-9210-DBEB0B4B95FA

P433

Q35188114-B8589042-E71E-4854-A15C-2608BA823531

P478

Q35188114-7D0BE328-BC49-4B37-B4E0-6C27A19B3F55

P577

Q35188114-57084EBE-C5F0-4DB7-A166-8F6BA5497DAD

P5875

Q35188114-C7FC1FC1-E4C6-49BC-BE40-3517E613E24B

P698

Q35188114-97A5D1CC-4131-41FF-B419-2D9DFC504CA9

P932

Q35188114-7B10DCD5-D78A-4A6C-A7B3-D08FFB6403D2

P356

J.SOC.2009.09.004

P1433

Surgical oncology clinics of North America

P1476

Randomized clinical trials in gastrointestinal stromal tumors

@en

P2093

Jason K Sicklick

http://www.w3.org/2001/XMLSchema#string

Peter A Learn

http://www.w3.org/2001/XMLSchema#string

Ronald P DeMatteo

http://www.w3.org/2001/XMLSchema#string

P2860

Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial

Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors

Contrast of response to dacarbazine, mitomycin, doxorubicin, and cisplatin (DMAP) plus GM-CSF between patients with advanced malignant gastrointestinal stromal tumors and patients with other advanced leiomyosarcomas.

A two-arm phase II study of temozolomide in patients with advanced gastrointestinal stromal tumors and other soft tissue sarcomas.

Effect of the tyrosine kinase inhibitor STI571 in a patient with a metastatic gastrointestinal stromal tumor.

Adjuvant imatinib mesylate after resection of localised, primary gastrointestinal stromal tumour: a randomised, double-blind, placebo-controlled trial.

Clinical management of gastrointestinal stromal tumors: before and after STI-571.

Progression-free survival in gastrointestinal stromal tumours with high-dose imatinib: randomised trial.

Outcome of patients with advanced gastro-intestinal stromal tumours crossing over to a daily imatinib dose of 800 mg after progression on 400 mg.

Phase III randomized, intergroup trial assessing imatinib mesylate at two dose levels in patients with unresectable or metastatic gastrointestinal stromal tumors expressing the kit receptor tyrosine kinase: S0033.

P304

101-113

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1016/J.SOC.2009.09.004

http://www.w3.org/2001/XMLSchema#string

P433

1

http://www.w3.org/2001/XMLSchema#string

P478

19

http://www.w3.org/2001/XMLSchema#string

P577

2010-01-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

38090526

http://www.w3.org/2001/XMLSchema#string

P698

19914562

http://www.w3.org/2001/XMLSchema#string

P932

3164338

http://www.w3.org/2001/XMLSchema#string